WHO ICTRP trial
A single center, open label, phase 2 study of Surufatinib combined with…
ChiCTR2100047313 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100047313 |
|---|---|
| Public title | A single center, open label, phase 2 study of Surufatinib combined with docetaxel as second line treatment in EGFR wild type non-squamous non-small-cell lung cancer patients |
| Scientific title | A single center, open label, phase 2 study of Surufatinib combined with docetaxel as second line treatment in EGFR wild type non-squamous non-small-cell lung cancer patients |
| Primary sponsor | Guangxi Medical University Affiliated Tumor Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 1-2 |
| Countries | China |
| Conditions | Non-small-cell lung cancer |
| Interventions | Group A:Surufatinib |
| Registration date | Jun 12, 2021 |
| Target size | Group A:45 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: